(Q36222741)

12 August 2017

1 reference

title

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis (English)

1 reference

12 August 2017

Thomas Hultsch

1

1 reference

12 August 2017

Alexander Kapp

series ordinal

2

1 reference

12 August 2017

Jonathan Spergel

series ordinal

3

1 reference

12 August 2017

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

211

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

174-187

1 reference

Atopic dermatitis and the atopic march

12 August 2017

cites work

1 reference

Sleep disturbances in children with atopic dermatitis

21 January 2018

1 reference

Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: an objective life quality measure.

21 January 2018

1 reference

Development of allergies and asthma in infants and young children with atopic dermatitis--a prospective follow-up to 7 years of age.

21 January 2018

1 reference

The immunogenetics of asthma and eczema: a new focus on the epithelium

21 January 2018

1 reference

Immune mechanisms leading to atopic dermatitis

21 January 2018

1 reference

Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized

21 January 2018

1 reference

Acquisition of immune function during the development of the Langerhans cell network in neonatal mice

21 January 2018

1 reference

Update on glucocorticoid action and resistance

21 January 2018

1 reference

Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids

21 January 2018

1 reference

Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis

21 January 2018

1 reference

Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells

21 January 2018

1 reference

The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis

21 January 2018

1 reference

Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies

21 January 2018

1 reference

0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial

21 January 2018

1 reference

Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study

21 January 2018

1 reference

Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis

21 January 2018

1 reference

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children

21 January 2018

1 reference

Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients

21 January 2018

1 reference

Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.

21 January 2018

1 reference

Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.

21 January 2018

1 reference

Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis

21 January 2018

1 reference

A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis

21 January 2018

1 reference

Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents

21 January 2018

1 reference

Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis.

21 January 2018

1 reference

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

21 January 2018

1 reference

Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells

21 January 2018

1 reference

Pimecrolimus does not affect Langerhans cells in murine epidermis

21 January 2018

1 reference

Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months

21 January 2018

1 reference

Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus

21 January 2018

1 reference

First experience of topical SDZ ASM 981 in children with atopic dermatitis

21 January 2018

1 reference

Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study

21 January 2018

1 reference

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis

21 January 2018

1 reference

A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis.

21 January 2018

1 reference

Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A.

21 January 2018

1 reference

SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis

21 January 2018

1 reference

Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants

21 January 2018

1 reference

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

21 January 2018

1 reference

Current management of atopic dermatitis and interruption of the atopic march

21 January 2018

1 reference

Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination

21 January 2018

1 reference

Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment

21 January 2018

1 reference

High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment.

21 January 2018

1 reference

Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000086739

1 reference

12 August 2017

1 reference